Enough of this crud about Z-944 and ZLC's not releasing the data. In plain, straight forth English, they state in the 8-K , " that is continuing progress in the clinic". That is about as clear as it can get.
If you can't put two and two together its time to reevaluate your position in ZLCS. If something had gone wrong they would have never said that.
I've read as many posts as I care to about the so called lack of info on Z-944. There that is not there and that is the fact. Some folks, on this board, are starting to look fairly foolish.
Jim Long and calm
Z944 Presented at the American Pain Society 2013 Annual Meeting
Z944 is a novel, oral, state-dependent, selective T-type calcium channel blocker that has demonstrated preclinical efficacy in multiple inflammatory pain models. T-type calcium channels have been recognized as key targets for therapeutic intervention in a broad range of cell functions and have been implicated in pain signaling. Zalicus completed Phase 1 single and multiple ascending dose clinical studies evaluating the safety and tolerability of Z944 in late 2012 and plans to continue further clinical development during 2013.